Quantcast
Last updated on April 19, 2014 at 8:28 EDT

Latest Clinical trial Stories

2014-01-29 16:28:39

Study Does Not Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif., Jan. 29, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the completion of the randomized, double-blind placebo-controlled Phase 2 study of KB003, its anti-GM-CSF monoclonal antibody (mAb), in patients with severe asthma. While the study showed that KB003 was generally safe and well tolerated, it did not meet its primary clinical endpoint of improvement in FEV(1) (a measurement of pulmonary...

2014-01-28 12:29:00

Annual Rare Disease Day event to benefit rare/orphan disease research CARLSBAD, Calif., Jan. 28, 2014 /PRNewswire/ -- Agility Clinical, Inc., a specialty consulting and contract research organization, and BIOCOM will host "Overcoming Challenges in Orphan Product Development", a special event in support of Rare Disease Day 2014 on February 27 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA. The event will feature speakers who are experts in orphan product...

2014-01-28 08:29:50

PLANTATION, Fla., Jan. 28, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President, Regulatory Affairs. All three new executives will report to Dr. James New, the Company's President and Chief Executive Officer. Dr. Richard Scheyer Dr. Richard Scheyer has 30 years of...

2014-01-28 04:21:01

NEWTOWN, Pa., Jan. 28, 2014 /PRNewswire/ -- BioClinica(®), Inc.,a global provider of clinical trial management services, announced today that Mundipharma Research, a dynamic pharmaceutical research and development company has selected BioClinica's OnPoint CTMS (Clinical Trial Management System). With this decision, Mundipharma Research plans to utilize OnPoint CTMS for various aspects of its clinical trial management activity. (Logo:...

2014-01-27 23:28:05

500-patient, real-world study of innovative, lowest profile EVAR system bolsters strong library of clinical evidence. Santa Rosa, CA (PRWEB) January 27, 2014 TriVascular, Inc. today announced the enrollment completion of the OVATION post-market registry, a 500-patient, 30-center European study. The multicenter prospective post-market registry evaluates the safety and performance of the Ovation and Ovation Prime™ Abdominal Stent Graft Systems, with patient follow-up out to five years....

2014-01-27 14:44:16

A new analysis of animal studies on cholesterol-lowering statins by UC San Francisco researchers found that non-industry studies had results that favored the drugs even more than studies funded by industry. The analysis of 63 animal studies of statins, led by Lisa Bero, PhD, UCSF professor clinical pharmacy, was published online January 21, 2014, in the scientific journal PLoS Biology. In previous studies, Bero determined that drug-company-sponsored clinical trials were associated with...

2014-01-27 12:29:38

WCCT Global will be at the 2014 Outsourcing in Clinical Trials West Coast to explain exciting new service offerings for 2014 COSTA MESA, Calif., Jan. 27, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern California, announced today that they will be exhibiting at the Outsourcing in Clinical Trials West Coast conference on January 28(th) - 29(th) in Burlingame, California. WCCT Global is excited to be in attendance because they will be...

2014-01-27 08:28:34

SAN DIEGO, Jan. 27, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx(®) Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen(®) for wound healing and as a biologics delivery platform. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Based on these...

2014-01-27 08:27:59

Expansion for Clinical and Other Programs; Long-Term Preparations for Eventual Commercialization BETHESDA, Md., Jan. 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into a set of agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L and DCVax-Direct products, development...

2014-01-27 08:27:50

Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE, N.J., Jan. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in...